cord blood-derived regulatory t cells: a novel cure for graft-versus-host-disease siddharth damania...
Post on 13-Jan-2016
217 Views
Preview:
TRANSCRIPT
Cord Blood-Derived Regulatory T Cells:A Novel Cure for Graft-Versus-Host-
Disease
Siddharth Damania2007
University of MinnesotaCancer Center
Bone-Marrow and Stem-Cell Transplants
http://www.vacationusarentals.com/images/usa_map.gif
6,000 Americans
Bone-Marrow and Stem-Cell Transplants
http://www.southalabama.edu/nursing/MSN%20Info/surgery_nurse.jpg
Bone-Marrow and Stem-Cell Transplants
http://www.southalabama.edu/nursing/MSN%20Info/surgery_nurse.jpg
Over half develop GVHD
Graft-Versus-Host-Disease (GVHD)
• GVHD occurs when transplanted cells reject host cells in the patient
Patient CellTransplanted
Cell
GVHD
GVHD
GVHD
GVHD
GVHD
Purpose
• To use T-reg cells to cure mice with human GVHD
First Goal
• To devise a new protocol to derive and purify CD4+25+ T-reg cells using human umbilical cord blood
Types of T cells
• Cytotoxic T cells• Helper T cells• T-reg cells
http://www.britannica.com/eb/art/print?id=85110&articleTypeId=0
CD4+25+ T-reg Cells
• Sakaguchi (2005)– Increased capability to suppress
immune responses– Low numbers increase risk of
autoimmune diseases
CD4+25+ T-reg Cells
• Sakaguchi (2005)– Increased capability to suppress
immune responses– Low numbers increase risk of
autoimmune diseases
• Suri-Payer et al (2006)– Potential to suppress multiple types
of autoimmune diseases
Umbilical Cord Blood
• Godfrey et al (2005)– T-reg cells isolated from peripheral
blood are often impure and require multiple purification processes
Umbilical Cord Blood
• Godfrey et al (2005)– T-reg cells isolated from peripheral
blood are often impure and require multiple purification processes
– Umbilical cord blood facilitates easier purification and presents purer quantities of T-reg cells
Procedure
Procedure
Procedure
Procedure
Procedure
CD4+25+ T-reg Cells
3/28 KT32
KT32 -41 BBL KT32 -OX40
FACS T-reg Cell Purity (CD4/CD25)
86.2% 95.4%
91.5% 81.0%
Second Goal
• To culture derived CD4+25+ T-reg cells
Second Goal
• To culture derived CD4+25+ T-reg cells
CD4+25+ T-reg Cells
Second Goal
• To culture derived CD4+25+ T-reg cells
CD4+25+ T-reg Cells
Second Goal
• To culture derived CD4+25+ T-reg cells
CD4+25+ T-reg Cells
CD4+25+ T-reg Cells
3/28 Cell Line
KT32 Cell Line
KT32-41BBL Cell Line
KT32-OX40L Cell Line
Culture Expansion of T-reg Cells
KT-32-OX40:y =
504.24e0.7776x
R2 = 0.7983
3/28:y =
10715e0.5056x
R2 = 0.8031
KT32-41BBL:y =
6.4462x5.0346
R2 = 0.8129
KT32:y =
8077.2x1.5986
R2 = 0.40660.00E+00
1.00E+06
2.00E+06
3.00E+06
4.00E+06
5.00E+06
6.00E+06
0 2 4 6 8 10 12 14
Day (After Umbilical Cord Blood Derivation)
Number of Cells
3/28'KT32KT32-OX40KT32-41BBLExpon. (KT32-OX40)Expon. (3/28')Power (KT32-41BBL)Power (KT32)
Culture Decline of T-reg Cells
3/28:
y = 3E+16x-8.5021
R2 = 0.6171
KT32:y = -14345x + 304762
R2 = 0.9924
KT32-OX40:y = -58036x + 2E+06
R2 = 0.3654
KT32-41BBL:y = -30548x +
719881
R2 = 0.5407
0.00E+00
1.00E+06
2.00E+06
3.00E+06
4.00E+06
5.00E+06
6.00E+06
14 15 16 17 18 19 20 21 22
Days (After Umbilical Cord Blood Derivation)
Number of Cells
3/28'
KT32
KT32-OX40
KT32-41BBL
Power (3/28')
Linear (KT32)
Linear (KT32-OX40)Linear (KT32-41BBL)
Third Goal
• To analyze the histological effect of CD4+25+ T-reg cells in GVHD mice
Procedure
Procedure
Procedure
GVHD
GVHD
GVHD
GVHD
GVHD
Procedure
GVHD
GVHD
GVHD
GVHD
GVHD
Procedure
GVHD
GVHD
GVHD
GVHD
GVHD
Healthy Liver
Diseased Liver
Diseased Liver
Diseased Liver
Diseased Liver
Diseased Liver
GVHD Reduction with T-reg Cells
Liver
GVHD Lung
GVHD Spleen GVHD
Colon GVHD
GVHD Mice 3.8 3.4 3.0 2.0 T-reg Treated Mice 1.9 1.9 3.6 1.1
GVHD Reduction with T-reg Cells
Liver
GVHD Lung
GVHD Spleen GVHD
Colon GVHD
GVHD Mice 3.8 3.4 3.0 2.0 T-reg Treated Mice 1.9 1.9 3.6 1.1
GVHD Reduction with T-reg Cells
Liver
GVHD Lung
GVHD Spleen GVHD
Colon GVHD
GVHD Mice 3.8 3.4 3.0 2.0 T-reg Treated Mice 1.9 1.9 3.6 1.1
GVHD Reduction with T-reg Cells
Liver
GVHD Lung
GVHD Spleen GVHD
Colon GVHD
GVHD Mice 3.8 3.4 3.0 2.0 T-reg Treated Mice 1.9 1.9 3.6 1.1
50%
GVHD Reduction with T-reg Cells
Liver
GVHD Lung
GVHD Spleen GVHD
Colon GVHD
GVHD Mice 3.8 3.4 3.0 2.0 T-reg Treated Mice 1.9 1.9 3.6 1.1
44%
GVHD Reduction with T-reg Cells
Liver
GVHD Lung
GVHD Spleen GVHD
Colon GVHD
GVHD Mice 3.8 3.4 3.0 2.0 T-reg Treated Mice 1.9 1.9 3.6 1.1
20%
GVHD Reduction with T-reg Cells
Liver
GVHD Lung
GVHD Spleen GVHD
Colon GVHD
GVHD Mice 3.8 3.4 3.0 2.0 T-reg Treated Mice 1.9 1.9 3.6 1.1
45%
Future Work
• Optimize culture expansion
Future Work
• Optimize culture expansion • Increase rate of cure in mice
Future Work
• Optimize culture expansion • Increase rate of cure in mice• Test T-reg cells as a therapeutic
cure for GVHD in humans
Acknowledgements• Dr. Keli Hippen• Dr. Paul Harker-Murray• The University of Minnesota• Lois Fruen• Advanced Science Research
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.QuickTime™ and a
TIFF (Uncompressed) decompressorare needed to see this picture.
Cord Blood-Derived Regulatory T Cells:A Novel Cure for Graft-Versus-Host-
Disease
Siddharth Damania2007
top related